BIOMAT Database Logo BIOMAT Database Logo

Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. 1997

J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
Department of Medicine, Medical College of Georgia, Augusta 30912-3190, USA.

BACKGROUND Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris. OBJECTIVE We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. METHODS Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. RESULTS Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, p < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. CONCLUSIONS Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial.
February 1997, Journal of the American Academy of Dermatology,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial.
January 2005, The Journal of dermatological treatment,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
A Randomized, Double-blind, Vehicle-controlled Trial of Luliconazole Cream 1% in the Treatment of Interdigital Tinea Pedis.
October 2014, The Journal of clinical and aesthetic dermatology,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis.
January 2003, Indian journal of dermatology, venereology and leprology,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris.
October 2011, Journal of drugs in dermatology : JDD,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
Studies on comparison of the efficacy of terbinafine 1% cream and butenafine 1% cream for the treatment of Tinea cruris.
July 2010, Indian dermatology online journal,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris.
January 1986, The Journal of international medical research,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. A double-blind, multicenter study.
February 1984, Archives of dermatology,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged ≥ 12 years with tinea cruris.
January 2014, Journal of drugs in dermatology : JDD,
J L Lesher, and D E Babel, and D M Stewart, and T M Jones, and L Kaminester, and M Goldman, and J S Weintraub
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial.
April 2007, The British journal of dermatology,
Copied contents to your clipboard!